Bevatas 400mg Bevacizumab Injection

Product Description

Bevatas 400mg Bevacizumab Injection contains Bevacizumab as its active ingredient. Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer by inhibiting angiogenesis (the process by which new blood vessels form), thus preventing tumors from getting the blood supply they need to grow.

Key Details about Bevatas 400mg Bevacizumab Injection:

Active Ingredient:

• Bevacizumab (400 mg per vial)

Common Uses:

Bevacizumab is commonly used to treat various cancers, including:

• Colorectal cancer
• Non-small cell lung cancer
• Breast cancer
• Renal cell carcinoma (kidney cancer)
• Glioblastoma (a type of brain cancer)
• Cervical cancer
• Ovarian cancer
• In some cases, it is also used for certain eye conditions like diabetic macular edema or wet age-related macular degeneration.

Mechanism of Action:

• Bevacizumab works by binding to vascular endothelial growth factor (VEGF), a protein responsible for promoting the growth of new blood vessels (angiogenesis). By inhibiting VEGF, Bevacizumab prevents the formation of new blood vessels that tumors need to grow and spread, effectively starving the tumor of nutrients and oxygen.

Dosage:

• The typical dose of Bevacizumab depends on the type of cancer being treated, as well as the patient™s weight and condition. The most common dosing is around 5 to 15 mg/kg, administered every 2 to 3 weeks.
• Bevatas 400mg is often used as part of a combination treatment with other chemotherapy drugs.
• It is given as an intravenous (IV) infusion over a period of time, typically lasting around 30 to 90 minutes depending on the specific treatment protocol.

Side Effects:

• Common Side Effects:
  • Fatigue
  • Hypertension (high blood pressure)
  • Diarrhea
  • Nausea and vomiting
  • Bleeding (nosebleeds, in particular)
  • Mouth sores or ulcers
• Serious Side Effects:
  • Gastrointestinal perforations (holes in the stomach or intestines)
  • Hemorrhage (serious bleeding)
  • Wound healing complications
  • Thromboembolic events (blood clots, including deep vein thrombosis, pulmonary embolism)
  • Heart problems, including heart failure
  • Kidney problems

Precautions:

• Monitoring: Regular monitoring is required for blood pressure, kidney function, wound healing, and for any signs of gastrointestinal or bleeding complications.
• Contraindications: Bevacizumab should not be used in patients who have had a recent surgery, wound healing problems, or active bleeding conditions.
• It™s important to inform the healthcare provider if the patient has a history of high blood pressure, heart disease, or blood clots.

Administration:

• Bevatas 400mg is administered intravenously by a healthcare professional in a controlled clinical setting to ensure proper monitoring for any adverse reactions.
•